Considerations for treatment duration in responders to immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) have improved overall survival for cancer patients, however, optimal duration of ICI therapy has yet to be defined. Given ICIs were first used to treat patients with metastatic melanoma, a condition that at the time was incurable, little attention was initially pa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Marron, Thomas U, Ryan, Aideen E, Reddy, Sangeetha M, Kaczanowska, Sabina, Younis, Rania H, Thakkar, Dipti, Zhang, Jiajia, Bartkowiak, Todd, Howard, Rachel, Anderson, Kristin G, Olson, Daniel, Naqash, Abdul Rafeh, Patel, Ravi B, Sachdev, Esha, Rodriguez-Ruiz, Maria E, Sheffer, Michal, Church, Sarah, Fuhrman, Christopher, Overacre-Delgoffe, Abigail, Nguyen, Rosa, Florou, Vaia, Thaxton, Jessica E, Aggen, David H, Guerriero, Jennifer L
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2021
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7929825/
https://ncbi.nlm.nih.gov/pubmed/33653801
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001901
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars